Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Desert herb and exercise combo targets belly fat and blood sugar

NCT ID NCT07486557

Disease control Sponsor: Beijing Sport University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether taking a daily Cistanche deserticola supplement along with moderate aerobic exercise (40 minutes, 3 times a week for 18 weeks) could improve body composition, insulin resistance, and inflammation in men aged 50-55 with central obesity. 125 men were randomly assigned to the combo treatment or usual lifestyle advice. Researchers measured changes in waist size, body fat, muscle mass, blood sugar, and inflammatory markers. The goal is to find a safe, effective way to boost metabolic health in this population.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cistanche deserticola extract
What this could lead to
If it works, this could point toward a natural supplement-plus-exercise approach to help men with central obesity improve metabolic health and reduce inflammation.
What could go wrong
This is a small, completed trial with 125 men, so results may not apply to other groups. The supplement may cause mild digestive discomfort, and benefits may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

125 people

The number who actually took part.

Started

Jun 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 55 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Chinese males aged 50 to 55 years. * Central obesity, defined as a waist circumference (WC) \> 90 cm and a body mass index (BMI) ≥ 25.0 kg/m². * A daily eating window of ≥ 14 hours. * Moderate-to-vigorous physical activity (MVPA) ≤ 150 minutes per week. * Sedentary time ≥ 8 hours per day. Exclusion Criteria: * Confirmed diagnosis of cardiovascular disease (CVD) or diabetes mellitus. * A history of alcohol consumption or tobacco use. * Diagnosis of conditions (e.g., arthritis) or presence of injuries that impair gait and limit exercise capacity. * Participation in other clinical trials within 4 weeks prior to enrollment. * Use of treatments or medications that may affect appetite or metabolism.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Central obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Inflammation inflammatory disease Insulin Resistance Obesity, Abdominal

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Central obesity Inflammation Insulin resistance

Contacts and locations

Locations

  • Beijing Sport University

    Beijing, Beijing Municipality, 100084, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.